ATLANTA, Oct. 26 /PRNewswire-FirstCall/ -- Inhibitex, Inc. announced today that it will host a conference call to review the Company's third quarter financial results and provide an update on recent corporate developments on Wednesday, November 2, 2005 at 5:00 p.m. Eastern Time. The Company will issue a press release regarding its third quarter financial results on the same day, prior to the conference call.
To access the conference call, please dial 800-711-8198 (domestic) or 617-597-5327 (international) and reference the access code 99384244. A replay of the call will be available from 7:00 p.m. Eastern Time on November 2, until December 2, 2005 at midnight. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 22976235. The archived webcast will be available in the Investors section of the Inhibitex website http://www.inhibitex.com under the Upcoming Events category.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. The Company currently has five drug development programs, all of which are based on its proprietary MSCRAMM protein platform technology. The Company's most advanced product candidates are Veronate, which is currently being evaluated in a Phase III clinical trial, and Aurexis, which is being evaluated in a Phase II clinical trial. The Company has retained all world-wide rights to Veronate and Aurexis, both of which have been granted Fast Track designation by the FDA. The Company's preclinical programs include a collaboration and joint development agreement with Dyax to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com.
Inhibitex(R), MSCRAMM(R), Veronate(R) and Aurexis(R) are registered trademarks of Inhibitex, Inc.
CONTACTS: Inhibitex, Inc. Russell H. Plumb Chief Financial Officer (678) 746-1136 rplumb@inhibitex.com Lilian Stern (Investors) Stern Investor Relations, Inc. (212) 362-1200 lilian@sternir.com Kathryn Morris (Media) KMorrisPR (845) 635-9828 kathryn@kmorrispr.com
Inhibitex, Inc.CONTACT: Russell H. Plumb, Chief Financial Officer of Inhibitex, Inc.,+1-678-746-1136, or rplumb@inhibitex.com; or Investors, Lilian Stern ofStern Investor Relations, Inc., +1-212-362-1200, or lilian@sternir.com; orMedia, Kathryn Morris of KMorrisPR, +1-845-635-9828, orkathryn@kmorrispr.com
Web site: http://www.inhibitex.com//
